22 January 2019 - Deborah Wilkes
GlaxoSmithKline (GSK), Galenica, Almirall and the US Council for Responsible Nutrition (CRN) have all recently announced people changes.
GSK's chairman stepping down
GSK has announced that Sir Philip Hampton is stepping down as non-executive chairman. Hampton joined GSK's Board on 1 January 2015, became deputy chairman in April 2015 and was made chairman the following month.
The company said it had started the process to find a replacement for Hampton.
Commenting on his decision to step down, Hampton said: "Following the announcement of our deal with Pfizer and the intended separation of the new consumer business, I believe this is the right moment to step down and allow a new chair to oversee the process through to its conclusion over the next few years and to lead the Board into this next phase for GSK."
Pfizer and GSK announced on 19 December 2018 that they had agreed to combine their consumer healthcare businesses into a "world-leading" joint venture with combined annual sales of around GBP9.8 billion (USD12.7 billion).
GSK pointed out that the move paved the way for its separation into two new UK-based companies focused on Pharmaceuticals/Vaccines and Consumer Healthcare (click here to read the News story).
Change of chair at Galenica
Galenica Group said Jörg Kneubühler would step down as chairman at the company's Annual General Meeting on 2 May 2019. Kneubühler has chaired the Swiss company since the Initial Public Offering (IPO) in April 2017.
Daniela Bosshardt-Hengartner will be proposed for election as the new chairwoman of the Board of Directors. She started her career as a pharmacist and joined the Board of Directors of the former Galenica Ltd in 2008.
Galenica said Markus Neuhaus would be put forward for election as a new Board member.
Almirall appoints chief digital officer
Almirall has appointed Francesca Domenech Wuttke as chief digital officer and member of the Management Board.
The Spanish pharmaceutical company said Wuttke would be responsible for "developing and executing the end-to-end digital strategy of the company". She will report to chief executive officer Peter Guenter.
Wuttke was previously managing director Europe for US-based Merck & Co's Global Health Innovation Fund which invests in digital health solutions and services.
New chair at US CRN
The CRN said RB Health's David Campbell had been elected chair of its Board of Directors. He takes over from Jim Hyde of Balchem Human Nutrition and Pharma.
Take out an Annual Subscription to the OTCToolbox website, giving you UNLIMITED ACCESS to all of our publications
* Premium News Stories
* OTCToolbox Innovations magazine NEW IDEAS BETTER WAYS
* OTCToolbox Deals Database
* News Extras
* OTC Deal Trends Briefing
* OTC Company Strategies Report
Helping you and your company make well-informed decisions
CLICK HERE TO FIND OUT MORE